Takeda’s Founding Family To Resign From Company Board
This article was originally published in PharmAsia News
Executive Summary
Japan's largest drug maker Takeda Pharmaceutical announced that one of the company's founding family members Kunio Takede will resign from his current position as chairman June 25. The position will be vacant for the time being. Kunio Takeda is the third son of the sixth generation of the Chobei Takeda family. Entering the company in 1962, Kunio Takeda was the only remaining Takeda family member sitting on the company's board. His resignation signals that the company is taking a decisively new business direction. (Click here for more - Japanese language
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.